OneSource Specialty Pharma: NSE & BSE give green signal for merger scheme; here's detailsOneSource Specialty Pharma: NSE & BSE give green signal for merger scheme; here's details

Introduction

Leading specialty pharma company received NSE and BSE no objection letters on February 25, 2026 for proposed composite scheme, subject to statutory approvals.

Also Read: Capacit’e Infraprojects bags ₹537 Cr LOI from Raymond arm, check details

Share price movement of OneSource Specialty Pharma

On February 27, 2026, Onesource Specialty Pharma Ltd opened at ₹1,323.50, up 0.28% from its previous close of ₹1,319.80. The stock reached a high of ₹1,323.55 (0.28%) and a low of ₹1,299.30. By 11:12 AM, it traded at ₹1,313.10, down 0.51%, with a market cap of ₹15,050.91 crore.

OneSource Receives Exchange Clearance

OneSource Specialty Pharma Limited received No Objection or No Adverse Observation letters from National Stock Exchange of India Limited and BSE Limited on February 25, 2026, for proposed composite scheme.

The scheme involves Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited and OneSource Specialty Pharma Limited under relevant applicable Indian and Singapore laws.

The letters are valid for six months. The proposed scheme remains subject to approvals from National Company Law Tribunal Mumbai, Singapore Court, shareholders, creditors and regulatory authorities and applicable bodies.

Stock performance of OneSource Specialty Pharma for period of 1 week, 6 months, and 1 year

Onesource Specialty Pharma Ltd delivered a 4.17% return over the past week, declined 30.1% in six months, and gained 3.05% over the past year.

Also Read: Premier Energies launches India’s first zero busbar solar cell; know what it means

Shareholding pattern of OneSource Specialty Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	29.90%	29.80%	29.80%
FII	19.20%	19.40%	18.70%
DII	18.80%	18.50%	18.10%
Public	32.00%	32.30%	33.40%

About OneSource Specialty Pharma

OneSource Specialty Pharma Ltd (NSE: ONESOURCE) is engaged in research, development, manufacture and commercialisation of biological injectable drug products and offers end to end CDMO services.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs